New Treatments for Childhood Leukaemia and Paediatric Cancers
Speaker: Dr Andrew Wood, Dept of Molecular Medicine & Pathology at U of Auckland and Paediatric Oncologist at Starship Children’s Hospital
Recipient of the AMRF Douglas Goodfellow Repatriation Fellowship in 2014
When: Thursday 1 June, 2017, 7 pm
Where: AMRF Auditorium, University of Auckland Medical School, 85 Park Road, Grafton
Tickets: Free, book by clicking here or via email to email@example.com or ring us on 09-923-1701
The goal of my AMRF funded research is to define the molecular signalling mechanisms that drive a newly defined subtype of Acute Myeloid Leukaemia (AML). Once we know this information we can start to develop new treatments with the goal of improving cure rates. For a long time choosing better chemotherapy and increasing doses led to steadily improving survival rates, but survival for paediatric AML has now plateaued at approximately 65%. This is because in recent trials survival gains from decreased leukaemia deaths have been largely offset by increased deaths from chemotherapy side effects. Molecularly targeted therapies tend to cause fewer toxic deaths compared to traditional chemotherapy, but the rate-limiting step is that we don’t know what targeted therapies to give. Basic research, like this AMRF funded project, is needed to help fill this gap in our knowledge.